AVID200’s Ability to Enhance Anti-tumor T-cell Activity and Promote Sensitivity to PD1 Blockade is Featured in a Poster Presentation at the 2018 BioCanRx Summit for Cancer Immunotherapy

On October 29, 2018 Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, reported a poster presentation demonstrating the ability of AVID200, an isoform selective TGF-β inhibitor, to enhance the anti-tumor activity of T-cells (Press release, Forbius, OCT 29, 2018, View Source [SID1234531669]). Notably, AVID200 significantly enhanced the activity of anti-PD-L1 immune checkpoint inhibition in vivo. This presentation highlights the collaborative work done with the laboratory of Dr. James Koropatnick, Director of the Strategic Training Program in Cancer Research and Technology Transfer at the London Health Sciences Centre. This research is sponsored by the previously announced peer-reviewed BioCanRx grant with a total project value of CAD$1,655,297, and BioCanRx contributing CAD$675,000.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About AVID200
Forbius developed AVID200 to be a highly potent and isoform-selective TGF-β inhibitor. AVID200 neutralizes TGF-β1 and-β3 with pM potency. These isoforms are known to be drivers of fibrosis and tumor immune resistance. In contrast, TGF-β2 is a positive regulator of hematopoiesis and normal cardiac function, and blockade of TGF-β2 is therefore undesirable. The ability of AVID200 to selectively target TGF-β1 and -β3 positions it to be an effective and well-tolerated therapeutic in fibrotic diseases and immuneoncology.